Background
Advanced or metastatic breast cancer (MBC) typically has a negative impact on health-related quality of life (HRQoL). Patients may experience pain and other physical symptoms due to increasing tumor burden and metastases [
1], and some may develop depression or anxiety related to the diagnosis, treatments, concerns about the future, and body image [
2,
3]. In addition, adverse events (AEs) related to MBC treatments can negatively affect HRQoL [
2].
Because available treatments for MBC are palliative rather than curative, preserving HRQoL is an important aspect of treatment selection, along with measures such as reducing tumor burden and prolonging progression-free survival (PFS) [
2,
4]. Thus, evaluation of HRQoL outcomes is particularly relevant in studies of MBC therapies.
Eribulin mesylate, a nontaxane microtubule dynamics inhibitor [
5], has demonstrated an overall survival benefit relative to other commonly used agents in patients who have received ≥2 prior MBC therapies, including an anthracycline and taxane [
6]. In a randomized, open-label, phase 3 study that compared eribulin with capecitabine for MBC treatment in women who had previously been treated with anthracyclines and taxanes [
7], HRQoL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life (QoL) (QLQ-C30) assessment tool [
8] and the Quality-of-Life Questionnaire for Breast Cancer (QLQ-BR23) [
9]. Scores for global health status (GHS)/QoL improved in both arms, with greater improvements in mean score for eribulin (13.5) than for capecitabine therapy (8.3). No significant differences were observed between the 2 groups, according to a linear mixed model (estimated treatment effect − 0.068,
P = 0.958) and pattern-mixture model (estimated treatment effect 0.082,
P = 0.949) [
7].
Trastuzumab is a human epidermal growth factor receptor 2 (HER2)-targeted humanized monoclonal antibody; previous clinical data have shown that the addition of trastuzumab to chemotherapy significantly improved overall survival, PFS, and disease-free survival relative to the use of chemotherapy alone in patients with HER2-positive (HER2+) MBC [
10,
11]. Studies of trastuzumab, as monotherapy or in combination with chemotherapy, have also demonstrated a beneficial effect on HRQoL in patients with HER2+ MBC [
12].
Recently, 2 phase 2 trials evaluating the use of eribulin ± trastuzumab as first-line therapy in locally recurrent or MBC were conducted. Eribulin monotherapy in patients with HER2-negative (HER2-) breast cancer (Study 206) [
13] demonstrated an objective response rate (ORR) of 28.6%, overall clinical benefit rate (CBR) of 51.8%, and PFS of 6.8 months. Combination therapy of eribulin plus trastuzumab as first-line therapy in patients with HER2+ breast cancer (Study 208) [
14] showed an ORR of 71.2%, CBR of 84.6%, and PFS of 11.6 months. The present secondary analysis was conducted to assess the HRQoL results from the first 6 treatment cycles of these phase 2 trials of eribulin ± trastuzumab as first-line therapy for locally recurrent or MBC.
Discussion
In these phase 2 studies, eribulin mesylate ± trastuzumab was evaluated as first-line therapy for locally recurrent or MBC. After 6 cycles, treatment did not lead to deterioration of overall HRQoL in most patients, with more than 60% of patients having stable/improved EORTC QLQ-C30 GHS/QoL scores. Minor differences were observed between the 2 trials, mainly in overall QOL with preservation over time in Study 208 and some deterioration in Study 206. Patients with stable/improved scores for the other items ranged from 51.7 to 93.2% in the QLQ-C30 and 50.0 to 100.0% in the QLQ-BR23 questionnaire. Most patients in both studies experienced improved pain (51.7 and 47.7%) and arm symptom scores (46.4 and 47.7%) with first-line eribulin, while most also had worsened cognitive functioning (48.3 and 45.5%). In Study 208, most patients also experienced worsened systemic therapy side effects (50%).
Significant correlations were observed between some of the most commonly reported AEs (fatigue, nausea and vomiting, pain, dyspnea, insomnia, constipation, and diarrhea) and corresponding HRQoL symptom items. Alopecia was a notable exception, due to a very limited number of responses for that item (n = 2 at cycle 6 for both studies). These correlations demonstrate consistency between investigator-reported adverse events and patient-reported outcomes.
It should be noted that as patients discontinued from the study, fewer patients were available for certain HRQoL assessments. For the scale of “upset by hair loss,” fewer than 10 patients for each timepoint and each visit were available. For the scale of “sexual enjoyment,” fewer than 10 patients for each time and each visit were available, with the exception of cycle 2 in which there were 11 patients. Similarly, the relatively small subgroups of responders and nonresponders hinder the ability to draw any conclusions regarding differences in HRQoL outcomes as a function of efficacy, or to evaluate whether HRQoL was a significant predictor of response as has been shown in other studies [
17‐
20]. A larger patient sample would help to better demonstrate the effects of eribulin ± trastuzumab on these and other aspects of HRQoL.
While combination chemotherapy for MBC provides higher ORR, longer times to progression, and a modest survival benefit, it is also associated with increased toxicity [
21]. A systematic review published in 2005 [
21] that compared the use of single-agent chemotherapy with combination chemotherapy for MBC analyzed 9 trials that evaluated QoL, only 4 of which found statistically significant differences. Of the 4 trials, 2 (Heidemann et al. [
22] and Joensuu et al. [
23]) found improved QoL with single-agent therapy. Heidemann et al. used Brunner’s score to assess QoL [
24] and found that single-agent therapy with mitoxantrone resulted in improved QoL scores for hair loss, nausea, and vomiting compared with combination chemotherapy. Joensuu et al. utilized the Rotterdam Symptom Checklist [
25] and found improved QoL scores for physical distress and nausea with epirubicin therapy compared with combination therapy. The remaining 2 studies (Nabholtz et al. [
26] and Simes et al. [
27]) reported mixed results. Using the EORTC QLQ-C30 questionnaire [
21], Nabholtz et al. [
26] reported that patients who received single-agent docetaxel experienced improved QoL scores for nausea/vomiting and loss of appetite while patients who received mitomycin and vincristine experienced improved QoL scores for role functioning and social functioning. Simes et al. [
27] reported improved QoL scores using the Spitzer QoL index [
28] during the first 3 months for pain, mood, and nausea and vomiting in the combination therapy group, but decreased QoL scores for hair loss compared with mitoxantrone monotherapy [
21]. A subsequent systematic review and meta-analysis of combination versus sequential single-agent therapies reported no significant difference in QoL, although only 3 of the 12 included trials reported on QoL [
29].
The results from Study 208 are generally consistent with those from a study of trastuzumab in combination with chemotherapy for HER2+ MBC, which also utilized the EORTC-QLQ-30 [
30]. In that study, patients treated with trastuzumab plus anthracycline/cyclophosphamide or paclitaxel chemotherapy (
n = 208) and patients treated with chemotherapy alone (
n = 192) had an initial worsening in fatigue, physical functioning, role functioning, social functioning, and global QoL at week 8 during treatment; patients in the trastuzumab plus chemotherapy group generally showed greater improvements in these domains following cessation of chemotherapy at week 20, with a statistically significantly greater improvement in fatigue at 32 weeks (
P < 0.05). In addition, the percentage of patients with improvement ≥10 points in global QoL was significantly greater among patients who received trastuzumab plus chemotherapy (51%) compared with the percentage among patients who received chemotherapy alone (36%;
P < 0.05 after Bonferroni correction) [
30]. In the CLEOPATRA study, HRQoL was evaluated using the Trial Outcome Index-Physical/Functional/Breast (TOI-PFB) of the Functional Assessment of Cancer Therapy-Breast (FACT-B) [
31]. In that study, patients (
n = 806) treated with trastuzumab plus docetaxel (with or without pertuzumab) showed an initial decline in mean QoL scores during the first 6 cycles, which then returned to baseline; the median time to deterioration was approximately 18 weeks [
31]. The timing of the decline in TOI-PFB scores relative to the timing of docetaxel discontinuation suggested that AEs associated with docetaxel may have been a factor [
31]. In the AVEREL study, which assessed HRQoL using the FACT-B scale, mean scores among patients treated with docetaxel and trastuzumab (
n = 174) decreased throughout the first 5 cycles, then increased at cycle 11, showing slight improvement over baseline; mean scores among patients who also received bevacizumab (
n = 185) remained relatively stable through cycle 5, then increased at cycle 11 [
32]. In a study that compared trastuzumab plus docetaxel (
n = 70) with trastuzumab emtansine (
n = 67), the median time to decrease of 5 or more points on the FACT-B TOI-PFB was 3.5 months in the trastuzumab plus docetaxel group and was 7.5 months in the trastuzumab–emtansine group (
P = 0.022) [
33].
Acknowledgments
The authors thank Rozena Varghese, PharmD, of MedVal Scientific Information Services, LLC, and Eli Berdougo, PhD, of Oxford PharmaGenesis Inc, for providing medical writing and editorial assistance, which was funded by Eisai, Inc.